The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2024 | Developing novel gene therapy approaches for hemoglobinopathies
Annarita Miccio, PhD, Imagine Institute of Genetic Diseases, Paris, France, discusses her talk on novel gene therapy approaches for beta hemoglobinopathies, highlighting that these new approaches will improve the safety, efficacy, and cost of the currently available gene therapies. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
